A megalin polymorphism associated with promoter activity and Alzheimer's disease risk

American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

Volumn 153, Issue 4, 2010, Pages 895-902

  Vargas, Teo ^a,b   Bullido, Maria Jesus ^b,c   Martinez Garcia, Ana ^b,c   Antequera, Desiree ^a,b   Clarimon, Jordi ^b,d   Rosich Estrago, Marcel ^e   Martin Requero, Angeles ^f   Mateo, Ignacio ^b,g   Rodriguez Rodriguez, Eloy ^b,g   Vilella Cuadrada, Elisabet ^e   Frank, Ana ^h   Lleo, Alberto ^b,d   Molina Porcel, Laura ^d   Blesa, Rafael ^d   Combarros, Onofre ^b,g   Gomez Isla, Teresa ^b,d   Bermejo Pareja, Felix ^a,b   Valdivieso, Fernando ^b,c   Carro, Eva ^a,b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^c CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^f CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^g HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; LUCIFERASE; MEGALIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN; TRANSCRIPTION INITIATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; FEMALE; GENES; GENOTYPE; HUMANS; LDL-RECEPTOR RELATED PROTEIN 2; MALE; MULTICENTER STUDIES AS TOPIC; POLYMORPHISM, GENETIC; REGULATORY SEQUENCES, NUCLEIC ACID; RISK FACTORS;

EID: 77952716596     PISSN: 15524841     EISSN: 1552485X     Source Type: Journal    
DOI: 10.1002/ajmg.b.31056     Document Type: Article

References (43)

1. Aoki K, Uchihara T, Sanjo N, Nakamura A, Ikeda K, Tsuchiya K, Wakayama Y. 2003. Increased expression of neuronal apolipoprotein E in human brain with cerebral infarction. Stroke 34:875-880. (Pubitemid 36402954)
2. Artiga MJ, Bullido MJ, Sastre I, Recuero M, Garcia MA, Aldudo J, Vazquez J, Valdivieso F. 1998. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett 421:105-108. (Pubitemid 28288072)
3. Aslanidis C, Schmitz G. 1999. High-speed apolipoprotein Egenotyping and apolipoprotein B3500 mutation detection using real-time fluorescence PCR and melting curves. Clin Chem 45:1094-1097. (Pubitemid 29340552)
4. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. 2007. Systematic meta-analyses of Alzheimer disease genetic association studies: The AlzGene database. Nat Genet 39:17-23. (Pubitemid 46026496)
5. Bertrand P, Poirier J, Oda T, Finch CE, Pasinetti GM. 1995. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Brain Res Mol Brain Res 33:174-178.
6. Bullido MJ, Artiga MJ, Recuero M, Sastre I, Garcia MA, Aldudo J, Lendon C, Han SW, Morris JC, Frank A, Vazquez J, Goate A, Valdivieso F. 1998.A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat Genet 18:69-71. (Pubitemid 28027883)
7. Bullido MJ, Guallar-Castillon P, Artiga MJ, Ramos MC, Sastre I, Aldudo J, Frank A, Coria F, Rodriguez-Artalejo F, Valdivieso F. 2000. Alzheimer's risk associated withhuman apolipoprotein E, alpha-2 macroglobulin and lipoprotein receptor related protein polymorphisms: Absence of genetic interactions, and modulation by gender. Neurosci Lett 289:213-216. (Pubitemid 30657976)
8. Carro E, Trejo JL, Busiguina S, Torres-Aleman I. 2001. Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy. J Neurosci 21: 5678-5684. (Pubitemid 32692166)
9. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I. 2002. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 8:1390-1397. (Pubitemid 36019424)
10. Carro E, Spuch C, Trejo JL, Antequera D, Torres-Aleman I. 2005. Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I. J Neurosci 25:10884-10893. (Pubitemid 41692618)
11. Christensen EI, Birn H. 2002. Megalin and cubilin: Multi-functional endocytic receptors. Nat Rev Mol Cell Biol 3:256-266. (Pubitemid 34619261)
12. Chun JT, Wang L, Pasinetti GM, Finch CE, Zlokovic BV. 1999. Glycoprotein 330/megalin (LRP-2) has low prevalence as mRNA and protein in brain microvessels and choroid plexus. Exp Neurol 157:194-201. (Pubitemid 29226882)
13. Coles R, Caswell R, Rubinsztein DC. 1998. Functional analysis of the Huntington's disease (HD) gene promoter. Hum Mol Genet 7:791-800. (Pubitemid 28221241)
14. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV. 2004. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43:333-344.
15. Deane R, Bell RD, Sagare A, Zlokovic BV. 2009. Clearance of amyloid-beta peptide across the blood-brain barrier: Implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 8:16-30.
16. Dietrich MO, Spuch C, Antequera D, Rodal I, de Yebenes JG, Molina JA, Bermejo F, Carro E. 2008. Megalin mediates the transport of leptin across the blood-CSF barrier. Neurobiol Aging 29:902-912. (Pubitemid 351601900)
17. Dudbridge F. 2003. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 25:115-121. (Pubitemid 37064867)
18. Fallin D, Cohen A, Essioux L, Chumakov I, Blumenfeld M, Cohen D, Schork NJ. 2001. Genetic analysis of case/control data using estimated haplotype frequencies: Application to APOE locus variation and Alzheimer's disease. Genome Res 11:143-151. (Pubitemid 32117960)
19. Garcia MA, Vazquez J, Gimenez C, Valdivieso F, Zafra F. 1996. Transcription factor AP-2 regulates human apolipoprotein E gene expression in astrocytoma cells. J Neurosci 16:7550-7556. (Pubitemid 26389694)
20. Gotthardt M, Trommsdorff M, Nevitt MF, Shelton J, Richardson JA, Stockinger W, Nimpf J, Herz J. 2000. Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. J Biol Chem 275:25616-25624.
21. HammadSM, Ranganathan S, Loukinova E, TwalWO,Argraves WS. 1997. Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide. J Biol Chem 272:18644-18649. (Pubitemid 27318206)
22. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Scḧurmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, J̈ockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA,O'Donovan M, Owen MJ, Williams J. 2009. Genome-wide association study identifies variants at CLUand PICALM associated with Alzheimer's disease. Nat Genet 41:1088-1093.
23. Heijmans BT, Slagboom PE, Gussekloo J, Droog S, Lagaay AM, Kluft C, Knook DL, Westendorp RG. 2002. Association of APOE epsilon2/epsilon3/epsilon4 and promoter gene variants with dementia but not cardiovascular mortality in old age. Am J Med Genet 107:201-208. (Pubitemid 34044891)
24. Holt SK, Karyadi DM, Kwon EM, Stanford JL, Nelson PS, Ostrander EA. 2008. Association of megalin genetic polymorphisms with prostate cancer risk and prognosis. Clin Cancer Res 14:3823-3831.
25. Horsburgh K, ColeGM, Yang F, Savage MJ, Greenberg BD, Gentleman SM, Graham DI, Nicoll JA. 2000. beta-amyloid (Abeta)42(43), abeta42, abeta40 and apoE immunostaining of plaques in fatal head injury. Neuropathol Appl Neurobiol 26:124-132.
26. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE. 2008. ApoE promotes the proteolytic degradation of Abeta. Neuron 58:681-693.
27. Kantarci S, Al-Gazali L, Hill RS, Donnai D, Black GC, Bieth E, Chassaing N, Lacombe D, Devriendt K, Teebi A, Loscertales M, Robson C, Liu T, MacLaughlin DT, Noonan KM, Russell MK, Walsh CA, Donahoe PK, Pober BR. 2007. Mutations in LRP2, which encodes the multiligand receptor megalin, cause Donnai-Barrow and facio-oculo-acoustico-renal syndromes. Nat Genet 39:957-959.
28. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fiévet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, the European Alzheimer's Disease Initiative Investigators, de PancorboMM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu? P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanché H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alpérovitch A, Lathrop M, Amouyel P, 2009. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41:1094-1099.
29. Lv H, Jia L, Jia J. 2008. Promoter polymorphisms which modulate APP expression may increase susceptibility to Alzheimer's disease. Neurobiol Aging 29:194-202.
30. Martinez-Garcia A, Sastre I, Tenorio R, Bullido MJ. 2004. SNP genotyping with FRET probes. Optimizing the resolution of heterozygotes. Mol Cell Probes 18:211-214.
31. Marzolo MP, von Bernhardi R, Bu G, Inestrosa NC. 2000. Expression of alpha(2)-macroglobulin receptor/low density lipoprotein receptor-related protein (LRP) in rat microglial cells. J Neurosci Res 60:401-411. (Pubitemid 30253604)
32. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. 1984. Clinical diagnosis of Alzheimer's disease: Report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944. (Pubitemid 14076461)
33. Moestrup SK, Verroust PJ. 2001. Megalin- and cubilin-mediated endocytosis of protein-bound vitamins, lipids, and hormones in polarized epithelia. Annu Rev Nutr 21:407-428.
34. Orlando RA, Rader K, Authier F, Yamazaki H, Posner BI, Bergeron JJ, Farquhar MG. 1998. Megalin is an endocytic receptor for insulin. J Am Soc Nephrol 9:1759-1766.
35. Page KJ, Hollister RD, Hyman BT. 1998. Dissociation of apolipoprotein and apolipoprotein receptor response to lesion in the rat brain: An in situ hybridization study. Neuroscience 85:1161-1171. (Pubitemid 28293421)
36. Selkoe DJ. 2001. Clearing the brain's amyloid cobwebs. Neuron 32: 177-180.
37. Thal DR, Capetillo-Zarate E, Schultz C, Rub U, Saido TC, Yamaguchi H, Haass C, Griffin WS, Del Tredici K, Braak H, Ghebremedhin E. 2005. Apolipoprotein E co-localizes with newly formed amyloid beta-protein (Abeta) deposits lacking immunoreactivity against N-terminal epitopes of Abeta in a genotype-dependent manner. Acta Neuropathol 110:459-471.
38. Trejo JL, Carro E, Torres-Aleman I. 2001. Circulating insulin-like growth factor I mediates exercise-induced increases in the number of new neurons in the adult hippocampus. J Neurosci 21:1628-1634. (Pubitemid 32182203)
39. Veinbergs I, Van Uden E, Mallory M, Alford M, McGiffert C, DeTeresa R, Orlando R, Masliah E. 2001. Role of apolipoprotein E receptors in regulating the differential in vivo neurotrophic effects of apolipoprotein E. Exp Neurol 170:15-26.
40. Wang CK, Chen CM, Chang CY, Chang KH, Chen IC, Li ML, Lee-Chen GJ, WuYR. 2006. alpha-Synuclein promoter RsaI T-to-C polymorphism and the risk of Parkinson's disease. J Neural Transm 113:1425-1433.
41. Wilson HS, Skodol A. 1994. Special report: DSM-IV: Overview and examination of major changes. Arch Psychiatr Nurs 8:340-347.
42. Zerbinatti CV, Wozniak DF, Cirrito J,CamJA, Osaka H, Bales KR,ZhuoM, Paul SM, Holtzman DM, Bu G. 2004. Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc Natl Acad SciUSA 101:1075-1080. (Pubitemid 38160586)
43. Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, Frangione B, Ghiso J. 1996. Glycoprotein 330/megalin: Probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci USA 93: 4229-4234.